奧賽康(002755.SZ)子公司擬向貴科藥業增資3600萬元 持股33.96%
格隆匯2月13日丨奧賽康(002755.SZ)公佈,公司子公司江蘇奧賽康藥業有限公司(以下簡稱“江蘇奧賽康”或“子公司”)擬以自有資金3600萬元向連雲港貴科藥業有限公司(以下簡稱“貴科藥業”)增資。增資完成後,江蘇奧賽康將獲得貴科藥業33.96%股權。江蘇奧賽康與貴科藥業及其股東孔寅、蘇州朗科生物技術股份有限公司(以下簡稱“朗科生物”)於2020年2月13日簽署了《投資協議書》。江蘇奧賽康全部投資款專款用於原料藥車間的新建,用來滿足江蘇奧賽康委託生產和加工需求。
貴科藥業是新型原料藥的研發、生產和銷售為一體的國家高新技術企業,擁有較為豐富的原料藥產業化和國際化的經驗,具有先進的技術、質量體系及優秀的人才儲備。貴科藥業的產品苯磺阿曲庫銨和卡培他濱已獲得GMP證書,來曲唑也已通過國家藥品監督管理局藥品審評中心批准,可以在上市制劑中使用,苯磺阿曲庫銨已獲得CEP證書,還有品種正在陸續申報認證過程中。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.